E Dorsey
Neurology · New York, NYNPI 1194759993
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $129,321 of the $144,689 with a category attached, or 89.4%. It is spread thinly across 16 manufacturers, the largest accounting for just 20.5%. Reporting peaked in 2020 at $39,205 and has fallen 89.9% since, to $3,965 in 2025. Among neurology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 98 payments — averaging $1476.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi US Services Inc.$30K
- Genentech, Inc.$16K
- Tanabe Pharma America, Inc.$15K
- AbbVie$12K
- Biogen$10K
- Eli Lilly$10K
- plus $52K from 10 others
Across 6 payments — averaging $1,387,083 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$8.1M
- Pfizer$188K
What the payments were for
- Consulting fees$129,32189%
- Speaking & faculty fees$10,8598%
- Travel & lodging$3,7623%
- Food & beverage$7471%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi US Services Inc. | 17 | $29,628 |
| Genentech, Inc. | 10 | $15,880 |
| Tanabe Pharma America, Inc. | 21 | $15,035 |
| AbbVie | 7 | $12,091 |
| Biogen | 2 | $10,455 |
| Eli Lilly | 3 | $9,750 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 7 | $8,532 |
| Sunovion Pharmaceuticals Inc. | 4 | $8,067 |
| Sanofi-aventis U.S. LLC | 6 | $7,400 |
| Spark Therapeutics, Inc. | 13 | $6,601 |
| Neurocrine Biosciences, Inc. | 2 | $6,340 |
| Merck | 2 | $6,278 |
| Boehringer Ingelheim | 1 | $2,620 |
| Otsuka America Pharmaceutical, Inc. | 1 | $2,592 |
| Genentech USA, Inc. | 1 | $2,070 |
| Acadia Pharmaceuticals Inc | 1 | $1,350 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NO PRODUCT DISCUSSED$10,165
- ABILIFY MYCITE$8,532
- INGREZZA$2,340
- Duopa$1,641
- NUPLAZID$1,350
How this compares
$144,689 in reported general payments places this provider in the 95th percentile of 1,623 neurology providers in New York.
Other neurology in New York
- Stephen KriegerNew York$1.1M
- Sheng-Han KuoNew York$657K
- Timothy VartanianNew York$468K
- Steven WolfNew York$428K
- David DodickNew York$426K
- David SimpsonNew York$403K
- Fred LublinNew York$383K
- Alexander ShtilbansNew York$374K
- Andrew LassmanNew York$359K
- Brian ApatoffNew York$295K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.